{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(1)"],"submitter":["Hamilton E"],"pubmed_abstract":["AC699 is a novel, orally bioavailable chimeric estrogen receptor-α (ERα) degrader that induces proteasome-dependent ERα degradation via cereblon E3 ligase recruitment. Here we report findings from a first-in-human, phase 1, dose-escalation study of once-daily AC699 (100-600 mg) in patients with heavily-pretreated, locally-advanced/metastatic ER-positive/HER2-negative breast cancer (ClinicalTrials.gov Identifier: NCT05654532). Primary objectives are to assess dose-limiting toxicities and treatment-emergent adverse events (TEAEs). Secondary objectives are to evaluate pharmacokinetics, objective response rate (ORR), clinical benefit rate (CBR, including stable disease ≥24 weeks), duration of response (DOR), and progression-free survival (PFS). Among 37 treated patients, TEAEs occurred in 78% "],"journal":["Nature communications"],"pagination":["796"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12824232"],"repository":["biostudies-literature"],"pubmed_title":["ER degradation for ER<sup>+</sup>/HER2- advanced or metastatic breast cancer: a phase 1 trial."],"pmcid":["PMC12824232"],"pubmed_authors":["Kim SY","Fan J","He W","Patel MR","Hamilton E","Zhang H","Cosgrove D","Layman RM","Danso M"],"additional_accession":[]},"is_claimable":false,"name":"ER degradation for ER<sup>+</sup>/HER2- advanced or metastatic breast cancer: a phase 1 trial.","description":"AC699 is a novel, orally bioavailable chimeric estrogen receptor-α (ERα) degrader that induces proteasome-dependent ERα degradation via cereblon E3 ligase recruitment. Here we report findings from a first-in-human, phase 1, dose-escalation study of once-daily AC699 (100-600 mg) in patients with heavily-pretreated, locally-advanced/metastatic ER-positive/HER2-negative breast cancer (ClinicalTrials.gov Identifier: NCT05654532). Primary objectives are to assess dose-limiting toxicities and treatment-emergent adverse events (TEAEs). Secondary objectives are to evaluate pharmacokinetics, objective response rate (ORR), clinical benefit rate (CBR, including stable disease ≥24 weeks), duration of response (DOR), and progression-free survival (PFS). Among 37 treated patients, TEAEs occurred in 78% ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-15T07:45:37.603Z","creation":"2026-07-01T03:08:03.364Z"},"accession":"S-EPMC12824232","cross_references":{"pubmed":["41407710"],"doi":["10.1038/s41467-025-67485-y"]}}